Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Late-stage nasopharyngeal carcinoma (NPC) frequently develops chemotherapy resistance, creating a significant unmet clinical need.
• Identifying novel therapeutic strategies to overcome chemoresistance in NPC is crucial for improving patient outcomes.

Purpose of the Study:

• To identify novel therapeutic targets and strategies to overcome paclitaxel resistance in nasopharyngeal carcinoma.
• To investigate the role of the multi-kinase inhibitor pacritinib in resensitizing NPC to paclitaxel.

Main Methods:

• Transcriptome analysis of paclitaxel-sensitive and -resistant NPC cell lines and clinical samples.
• Investigated the effect of pacritinib on IRAK1 phosphorylation and S100A9 expression.
• Utilized in vitro and in vivo models to assess the impact of IRAK1 blockade and combined pacritinib-paclitaxel treatment.

Main Results:

• Pacritinib resensitized acquired paclitaxel resistance in NPC models.
• S100A9 was identified as a key gene suppressed by pacritinib, with its overexpression linked to paclitaxel resistance and poor prognosis.
• Pacritinib inhibited IRAK1 phosphorylation, leading to decreased S100A9 expression. Genetic or pharmacologic blockade of IRAK1 overcame paclitaxel resistance.
• Combined pacritinib and paclitaxel treatment demonstrated superior antitumor effects.

Conclusions:

• The IRAK1-S100A9 axis plays a critical role in mediating paclitaxel resistance in nasopharyngeal carcinoma.
• Targeting IRAK1 with pacritinib presents a promising therapeutic strategy to overcome chemoresistance in NPC.
• This study highlights a novel approach for treating advanced nasopharyngeal carcinoma with acquired chemoresistance.